| breast cancer - HR positive | |||||
| la/mBC - HR positive | la/mBC - HR positive - (neo)adjuvant (NA) | la/mBC - HR-positive - 2nd line (L2) | la/mBC - HR positive - L2 - all population | la/mBC - HR positive - L2 - PIK3CA mutant | |
| buparlisib based treatment | |||||
| buparlisib plus fulvestrant | BELLE-2 ... | BELLE-2 ... | BELLE-2 ... | ||
| buparlisib plus letrozole | |||||